{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:15:04Z","timestamp":1778879704955,"version":"3.51.4"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Interstitial lung diseases (ILDs) comprise a family of heterogeneous entities, primarily characterised by chronic scarring of the lung parenchyma. Among ILDs, idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonitis, associated with progressive functional decline leading to respiratory failure, a high symptom burden, and mortality. Notably, the incidence of lung cancer (LC) in patients already affected by ILDs\u2014mainly IPF\u2014is significantly higher than in the general population. Moreover, these cases are often neglected and deprived of active oncologic treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We here aim to identify variables predictive of outcome (mortality) in a multicentre retrospective cohort of ILD associated with lung cancer, collected from 2018 to the end of 2023. Overall, 73 cases were identified, and exhaustive clinicopathologic data were available for 55 patients. Among them, 42 had IPF. The entire dataset was then analysed by using the JMP partition algorithm (JMP-Statistical Discoveries, from SAS), which can choose the optimum splits from many possible trees, making it a powerful modelling and data discovery tool.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The average age at lung cancer diagnosis was 71.4 years, whereas the average age at IPF diagnosis was 69.5 years. The average Charlson Comorbidity Index was 4.6. Female patients constituted 28.3% (15) of the evaluated cases. The most frequent tumour histotype was adenocarcinoma (45.2%), and in more than 60% of the cases (67.9%), cancer was diagnosed at an early stage (TNM I\u2013II\u2013IIIA). A significant gender difference emerges regarding the overall patient survival, and quite unexpectedly, surgical approach to IPF-associated LC and the detection of serum autoantibodies are among the strongest outcome predictors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The analysis performed is descriptive and successfully identifies key features of this specific and rare cancer population. IPF-associated LC emerges as a unique malignant disease defined by specific gender and histopathologic clinical and molecular parameters, which might benefit from active treatments.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1488157","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:11:12Z","timestamp":1734412272000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Interstitial lung diseases with concomitant lung cancer: a data mining approach revealing a complex condition with gender- and immune-associated specific implications"],"prefix":"10.3389","volume":"14","author":[{"given":"Fabio","family":"Perrotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donato","family":"Lacedonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"D\u2019Agnano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Scioscia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Pia","family":"Foschino Barbaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lettieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Frate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Mancinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Piloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiberio","family":"Oggionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra","family":"Bortolotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Carrozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isa","family":"Cerveri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Guido Corsico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia Maria","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001291","article-title":"Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review","volume":"10","author":"Shah Gupta","year":"2023","journal-title":"BMJ Open Respir Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.11.037","article-title":"Pictorial review of fibrotic interstitial lung disease on high resolution CT scan and updated classification","volume":"165","author":"Brixey","year":"2024","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12931-023-02554-8","article-title":"Walking the path of treatable traits in interstitial lung diseases","volume":"24","author":"Amati","year":"2023","journal-title":"Respir Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2102146","DOI":"10.1183\/13993003.02146-2021","article-title":"The role of precision medicine in interstitial lung disease","volume":"60","author":"Maher","year":"2022","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12890-023-02340-8","article-title":"Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study","volume":"23","author":"Lee","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1183\/09031936.00077309","article-title":"Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology","volume":"35","author":"Vancheri","year":"2010","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2014.05.002","article-title":"Activation of oncogenic pathways in idiopathic pulmonary fibrosis","volume":"7","author":"Stella","year":"2014","journal-title":"Transl Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202309-1573PP","article-title":"Idiopathic pulmonary fibrosis: from common microscopy to single-cell biology and precision medicine","volume":"9","author":"Selman","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00115-2022","article-title":"Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges","volume":"8","author":"Kewalramani","year":"2022","journal-title":"ERJ Open Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/resp.14363","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis: A retrospective multicentre study in Europe","volume":"28","author":"Karampitsakos","year":"2023","journal-title":"Respirology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2022.2145948","article-title":"Idiopathic pulmonary fibrosis and lung cancer: targeting the complexity of the pharmacological interconnection","volume":"16","author":"Perrotta","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"362 387","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO classification of lung tumors: impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11071010","article-title":"Lung-seeking metastases","volume":"11","author":"Stella","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-12","article-title":"Cancers of unknown primary origin: current perspectives and future therapeutic strategies","volume":"10","author":"Stella","year":"2012","journal-title":"J Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00825","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183023","article-title":"Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms","volume":"12","author":"Lie","year":"2017","journal-title":"PLoS One"},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12672-023-00615-4","article-title":"Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer","volume":"14","author":"Kaira","year":"2023","journal-title":"Discovery Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12967-021-02898-z","article-title":"Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer","volume":"19","author":"Pan","year":"2021","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15907","DOI":"10.1038\/s41598-021-95372-1","article-title":"Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma","volume":"11","author":"Liu","year":"2021","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9210","article-title":"Next-generation sequencing-based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 mutations in patients with non-small cell lung cancer","volume":"18","author":"Jing","year":"2018","journal-title":"Mol Med Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083607","article-title":"Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy)","volume":"8","author":"de Biase","year":"2013","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107970","article-title":"Cost-effectiveness of next-generation sequencing for advanced EGFR\/ALK-negative non-small cell lung cancer","volume":"197","author":"Kang","year":"2024","journal-title":"Lung Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur Respir J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"17534666231181537","DOI":"10.1177\/17534666231181537","article-title":"Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective","volume":"17","author":"Mai","year":"2023","journal-title":"Ther Adv Respir Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1759720X211032457","DOI":"10.1177\/1759720X211032457","article-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders","volume":"13","author":"Kuwana","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2019.03.007","article-title":"Autoantibodies in interstitial lung diseases","volume":"51","author":"Stevenson","year":"2019","journal-title":"Pathology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10235562","article-title":"PD-L1 expression in patients with idiopathic pulmonary fibrosis","volume":"10","author":"Kronborg-White","year":"2021","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00028.2023","article-title":"IL-8 concurrently promotes idiopathic pulmonary fibrosis mesenchymal progenitor cell senescence and PD-L1 expression enabling escape from immune cell surveillance","volume":"324","author":"Yang","year":"2023","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1022228","article-title":"The role of PD-1\/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-024-04884-7","article-title":"Inhibitor of PD-1\/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis","volume":"22","author":"Tan","year":"2024","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12931-023-02551-x","article-title":"Expression of PD-1\/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis","volume":"24","author":"Karampitsakos","year":"2023","journal-title":"Respir Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-880","article-title":"The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review","volume":"11","author":"Stella","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255375","article-title":"Survival analysis in lung cancer patients with interstitial lung disease","volume":"16","author":"Alomaish","year":"2021","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/eva.13167","article-title":"Why women have more autoimmune diseases than men: An evolutionary perspective","volume":"14","author":"Kronzer","year":"2020","journal-title":"Evol Appl"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1142723","article-title":"Sex and gender influence on immunity and autoimmunity","volume":"14","author":"Lahita","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3201\/eid1011.040367","article-title":"Women and autoimmune diseases","volume":"10","author":"Fairweather","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713698","article-title":"Gender differences in idiopathic pulmonary fibrosis: are men and women equal","volume":"8","author":"Ses\u00e9","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-014-1071-5","article-title":"Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis","volume":"45","author":"Iwata","year":"2015","journal-title":"Surg Today"},{"key":"B42","doi-asserted-by":"publisher","first-page":"220147","DOI":"10.1183\/20734735.0147-2022","article-title":"Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges","volume":"18","author":"Abu Qubo","year":"2022","journal-title":"Breathe (Sheff)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.07.001","article-title":"Clinical significance of autoantibody positivity in idiopathic pulmonary fibrosis","volume":"155","author":"Ghang","year":"2019","journal-title":"Respir Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2102381","DOI":"10.1183\/13993003.02381-2021","article-title":"Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis","volume":"61","author":"Koether","year":"2023","journal-title":"Eur Respir J"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2300653","DOI":"10.1183\/13993003.00653-2023","article-title":"A novel take on idiopathic pulmonary fibrosis disease progression: localised autoimmunity","volume":"61","author":"Mukherjee","year":"2023","journal-title":"Eur Respir J"},{"key":"B46","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s12016-022-08930-4","article-title":"Systemic sclerosis association with Malignancy","volume":"63","author":"Lepri","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.003","article-title":"Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature","volume":"12","author":"Colaci","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.10.023","article-title":"Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients","volume":"150","author":"Li","year":"2020","journal-title":"Lung Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41467-019-08887-7","article-title":"The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.964722","article-title":"Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break","volume":"9","author":"Kirgou","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.09.001","article-title":"Pathology of idiopathic pulmonary fibrosis assessed by a combination of microcomputed tomography, histology, and immunohistochemistry","volume":"190","author":"Tanabe","year":"2020","journal-title":"Am J Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30356-X","article-title":"Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study","volume":"8","author":"Verleden","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1437767","article-title":"Tertiary lymphoid structures and B-cell infiltration are IPF features with functional consequences","volume":"15","author":"Cocconcelli","year":"2024","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.05.015","article-title":"Immune mechanisms in fibrotic interstitial lung disease","volume":"187","author":"Kamiya","year":"2024","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"663 671","DOI":"10.1111\/apm.13445","article-title":"Changes in T-cell subsets occur in interstitial lung disease and may contribute to pathology via complicated immune cascade","volume":"132","author":"Karaselek","year":"2024","journal-title":"APMIS"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1488157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T05:11:17Z","timestamp":1734412277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1488157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":55,"alternative-id":["10.3389\/fonc.2024.1488157"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1488157","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"article-number":"1488157"}}